Few people noticed. And he’s not alone in this!
Insider info?

I used excerpts form this video.

This happened last days of may, followed shortly by:

Insider Selling: Alphabet Inc. (NASDAQ:GOOG) CAO Sells 42 Shares of Stock

Posted by MarketBeat News on Jun 3rd, 2022

   Alphabet Inc. (NASDAQ:GOOG – Get Rating) CAO Amie Thuener O’toole sold 42 shares of the business’s stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $2,298.63, for a total transaction of $96,542.46. Following the completion of the transaction, the chief accounting officer now owns 1,181 shares of the company’s stock, valued at $2,714,682.03. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Amie Thuener O’toole also recently made the following trade(s):Get Alphabet alerts: 

  • On Tuesday, May 3rd, Amie Thuener O’toole sold 42 shares of Alphabet stock. The stock was sold at an average price of $2,335.30, for a total transaction of $98,082.60.
  • On Friday, April 1st, Amie Thuener O’toole sold 42 shares of Alphabet stock. The stock was sold at an average price of $2,800.20, for a total transaction of $117,608.40.

NASDAQ GOOG traded up $72.18 on Thursday, hitting $2,354.92. 1,373,569 shares of the company were exchanged, compared to its average volume of 1,582,973. The company has a market cap of $1.55 trillion, a PE ratio of 21.30, a PEG ratio of 1.07 and a beta of 1.13. Alphabet Inc. has a 12 month low of $2,044.16 and a 12 month high of $3,042.00. The stock has a fifty day moving average of $2,464.33 and a 200-day moving average of $2,675.68. The company has a current ratio of 2.87, a quick ratio of 2.85 and a debt-to-equity ratio of 0.06.

Shares of Alphabet are scheduled to split on Monday, July 18th. The 20-1 split was announced on Tuesday, February 1st. The newly minted shares will be payable to shareholders after the closing bell on Friday, July 15th.

Alphabet (NASDAQ:GOOG – Get Rating) last released its quarterly earnings data on Tuesday, April 26th. The information services provider reported $24.62 earnings per share for the quarter, missing analysts’ consensus estimates of $25.51 by ($0.89). Alphabet had a net margin of 27.57% and a return on equity of 30.18%. During the same quarter in the prior year, the business earned $26.29 earnings per share. On average, analysts expect that Alphabet Inc. will post 112.46 earnings per share for the current year.

GOOG has been the subject of a number of research analyst reports. Tigress Financial upped their price objective on shares of Alphabet from $3,540.00 to $3,670.00 in a research report on Friday, March 18th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Alphabet from $3,150.00 to $2,900.00 in a research report on Wednesday, April 27th. Canaccord Genuity Group upped their price target on shares of Alphabet from $3,350.00 to $3,500.00 and gave the company a “buy” rating in a research report on Wednesday, February 2nd. Cowen upped their price target on shares of Alphabet from $3,500.00 to $3,600.00 and gave the company an “outperform” rating in a research report on Wednesday, February 2nd. Finally, Wedbush restated an “outperform” rating on shares of Alphabet in a research report on Wednesday, April 20th. One investment analyst has rated the stock with a hold rating and thirty have assigned a buy rating to the company. According to data from MarketBeat.com, Alphabet presently has a consensus rating of “Buy” and a consensus price target of $3,308.77.

Several institutional investors have recently added to or reduced their stakes in GOOG. Morgan Stanley lifted its stake in shares of Alphabet by 2.1% in the second quarter. Morgan Stanley now owns 2,433,132 shares of the information services provider’s stock valued at $6,098,209,000 after buying an additional 50,601 shares in the last quarter. New World Advisors LLC purchased a new stake in shares of Alphabet in the third quarter valued at about $724,000. EagleClaw Capital Managment LLC raised its holdings in shares of Alphabet by 3.5% in the third quarter. EagleClaw Capital Managment LLC now owns 2,946 shares of the information services provider’s stock valued at $7,853,000 after purchasing an additional 99 shares during the last quarter. Legacy Wealth Planning LLC purchased a new stake in shares of Alphabet in the third quarter valued at about $205,000. Finally, BloombergSen Inc. raised its holdings in shares of Alphabet by 1.4% in the third quarter. BloombergSen Inc. now owns 45,471 shares of the information services provider’s stock valued at $121,180,000 after purchasing an additional 616 shares during the last quarter. 31.20% of the stock is currently owned by hedge funds and other institutional investors.

About Alphabet

Alphabet Inc provides various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment offers products and services, including ads, Android, Chrome, hardware, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube.

MarketBeat News

So Alphabet stock doesn’t seem to be currently underperforming. If the cause of all these evolutions is not something happening in the present, Gates and the Alphabet CAO could very well have information about something in the future that determined them to take action. Insider info?

As for publicly available info on Alphabet’s future, the only notable event announced is:

Google parent Alphabet announced a 20-for-1 stock split. Here’s what that means and how it will impact investors – CNBC

In short, that means Alphabet shares aren’t many and they are expensive. It also means the current owners are not trading them enough to create speculative value growth. So they split every share in 20 tinier shares with the same total value. Those are bite-sized shares that smaller sharks can take on.

What that also means is that Alphabet needs funds and the little closed circle of rich elite stockholders isn’t providing enough, the actual business is not making much either, so they need to raise more from market speculations. The strategy chosen to achieve this:
They lower their pants a bit for easier plebeian access, in hope they will get access to more plebeian pockets in return.

While all this info might not be enough to derive definitive and specific conclusion about the future of these two pillars of the digital dome, namely Alphabet and Microsoft, a few things can be said with close to 100% certainty:

Extraordinary evolutions have extraordinary causes.

The Military BioTech Complex will have to transform and adapt to the extraordinary change it’s causing. That will reflect in its corporate avatars.

If Twitter is going through a self-inflicted crisis, it’s hardly possible for Google to fully avoid something similar, for the same reasons.
I’d guess Google should suffer even more from user backlash by now, because their offer is even easier to replace, but they’re just better at hiding it and there’s no Elon Musk to look under their hood.

Microsoft’s public image is inextricably tied to Bill Gates’, whose credibility took the most spectacular nosedive last couple of years.

These previous four statements might be one and the same.

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

Sometimes my memes are 3D. And you can own them. Or send them to someone.
You can even eat some of them.
CLICK HERE

We found a contractual clause between governments and Covid jabs manufacturers that may end the pandemic no later than this summer.

A question from Sky News, we know better because we can critically analyze their reports better than they do

We’ve just learned that AstraZeneca (and likely other vaccine manufacturers) can’t properly milk their new cash cow before the pandemic is over. Several of the biggest contracts closed so far between governments and vaccine manufacturers stipulate that profits won’t be paid before the pandemic is officially declared over.

AstraZeneca, which has promised not to profit from its Covid-19 vaccine “during the pandemic”, has the right to declare an end to the pandemic as soon as July next year, according to a document seen by the Financial Times.

An Oxford University press release confirms:
“A key element of Oxford’s partnership with AstraZeneca is the joint commitment to provide the vaccine on a not-for-profit basis for the duration of the pandemic across the world, and in perpetuity to low- and middle-income countries. “

Also, according to Sky News Australia, “AstraZeneca has committed that the vaccine will be made on a not-for-profit basis as long as COVID-19 is classified as a pandemic, and will remain so when sold to developing nations.
Should the disease recede and the vaccine become an annual defence against COVID-19 sold at a profit, Professor Gilbert, her close colleagues, the university, and a range of private and corporate investors – including Google’s parent company Alphabet – all stand to benefit.”

Note that AstraZeneca is a member of the World Economic Forum (think The Great Reset), same as Pfizer, Moderna and J&J, and Google is a shareholder, so they have amassed more support than a country can raise.

These claims are also supported by their main partners in AstraZeneca, Oxford Science Innovation, who says:
“In the interest of accelerating global vaccine development, Vaccitech assigned its rights to the vaccine candidate to Oxford University Innovation, to facilitate the licence of those rights to AstraZeneca for the development and manufacture of the vaccine. None of the parties will profit from vaccine sales during the pandemic.
Vaccitech is backed by leading investment institutions, including GV (formerly Google Ventures), Sequoia Capital China, Liontrust (formerly Neptune), Korea Investment Partners and Oxford Sciences Innovation.”

So Google is a Pharmafia giant who also controls the media and can censor any inconvenient report on its services and products

The problem is that the propaganda and the fear porn didn’t work as they hoped (nothing does when you’re as deranged as they are) and the governments are way behind the schedule with inoculations and other related affairs, hence the prolonged lockdowns in some parts of the world. If they open in summer, they will lose even more customers and they can’t use the emergency situation excuse to inject people with hazardous untested chemicals like these mRNA jabs.


This is what obliges Google and the Gang to ramp up censorship and propaganda.
So now Pharmafia insiders (lower level salesmen) inform us that the powers behind these covid jabs are pressuring governments to end the pandemic and start the payments. But that’s hardly achievable and politicians find themselves between a rock and a hard place.


We’ve said before that this state of emergency has no end in sight because it’s a necessary condition for injecting experimental garbage into the gullible masses. It was mostly true but we’ve already corrected that statement because this new revelation might just bring that end.


Some governments may be able to win a few extra-months, but it’s very likely that many will not have that power and will do whatever stunt necessary to please their Pharmafia overlords.

This is how you may explain the unexplainable recent plunge in case stats too.
As we showed before, they have a knob that can control the stats: the PCR test cycle threshold. The higher, the more positive results.
As the pandemic was scheduled to ease and the covid business to normalize after Biden/WEF’s hostile takeover of US Government, WHO ordered lowering the threshold precisely on Biden’s inauguration day and these are the immediate results. Which also proves how they pumped up the numbers before.

Financial Times goes into details:
<<While some companies said from the outset they can only develop the vaccine for profit, others, such as AstraZeneca and Johnson & Johnson, have agreed to provide doses on a cost basis for at least as long as the pandemic lasts.
The memorandum of understanding, seen by the FT, outlines the conditions of a deal signed in July between AstraZeneca and Fiocruz, a Brazilian public health institution, to produce at least 100m vaccine doses, worth more than $300m.The document states that for the purposes of the MoU and the “Definitive Agreements” the pandemic will be considered over on July 1, 2021. The so-called “Pandemic Period” could be extended but only if “AstraZeneca acting in good faith considers that the SARS-COV-2 pandemic is not over”, it says. 

Pascal Soriot, AstraZeneca’s chief executive, has previously said that a number of factors would influence the company’s assessment of when the pandemic is over, including the World Health Organisation’s own analysis, but has not been more specific. He has also declined to disclose a post-pandemic price point.
The WHO declared the current outbreak a pandemic in March. More than 1m have died and cases globally show no sign of tapering. Even optimistic forecasts predict an approved vaccine is unlikely to be widely available for public vaccination campaigns before the middle of next year.
AstraZeneca declined to answer specific questions regarding its definition of the “Pandemic Period” or the Fiocruz agreement.
“From the outset, AstraZeneca’s approach has been to treat the development of the vaccine as a response to a global public health emergency, not a commercial opportunity,” the company said in a statement. “We continue to operate in that public spirit and we will seek expert guidance, including from global organizations, as to when we can say that the pandemic is behind us.”
Oxford university also declined to respond to specific questions. “The terms of our agreement are confidential but uphold Oxford’s commitment to fair and equitable access to the vaccine for the duration of the pandemic should it prove to be effective in our global phase 3 clinical trials,” the university said.
Public health experts say many of the vaccine deals, including those involving AstraZeneca, are shrouded in secrecy, offering little room for scrutiny.

Manuel Martin, medical innovation and access policy adviser at Médecins Sans Frontières, said the terms of the Fiocruz MoU gave AstraZeneca “an unacceptable level of control over a vaccine developed through public funds”. “Relying on voluntary measures by pharmaceutical corporations to ensure access is a mistake with fatal consequences,” he said.
AstraZeneca has received large amounts of public money to develop its vaccine and secure forward orders, including at least $1bn from the US. Supply deals to date indicate that the vaccine, which requires two doses, is priced at about $3 to $4 per dose, lower than the prices disclosed or reported for other potential vaccines.
Ellen Hoen, director of Medicines Law & Policy, a non-profit campaigning for greater access to medicines, said more transparency was needed.
“Despite all the talk about the Covid-19 vaccine needing to be a ‘global public good’ by political leaders who spend billions on Covid-19 R&D, it seems that it is the drug companies that determine, in secret deals, who will get access to the vaccine and when,” she said.>>

If this trend keeps going on a bit longer, it very likely means that they are staying on the course and many countries will officially end the pandemic starting June/July.

And that will force them do more stupid stunts we can’t wait to expose.
They already are stumbling at all levels, from production and distribution to research. Last minute news from Financial Times inform that “Scientists are demanding to know why AstraZeneca’s paused trial of its Covid-19 vaccine is still on hold in the US while it has been restarted elsewhere, worrying it could damage public trust there. The trial was originally halted because a UK participant developed a serious inflammatory condition. In the US, it has been on hold for almost two weeks, while trials in other countries including the UK have restarted.
Ashish Jha, dean of the school of public health at Brown University, said: “Normally, companies wouldn’t give out information in the middle of a trial, but this is an exceptional case and we need to have radical transparency. Otherwise, there is a risk the public will lose confidence in the whole process.”
AstraZeneca is telling participants in resumed trials that the “unexplained neurological symptoms” were either unlikely to be associated with the vaccine or that there was “insufficient evidence” to say whether they were or were not associated, and so independent reviewers had recommended that vaccinations continue. Clinical trials do not usually publish data before hitting pre-determined milestones.”

LAST MINUTE UPDATE: This came in hours after we published this. Ah, well…

Source

As a side note: watch the video from the above source and everything featuring Fauci this year and tell me he didn’t have better energy and mood during Trump’s mandate. I blame that on the fact that Trump was the best pro-vaccine campaigner they had and now that he’s gone from the screens, they’re in shambles. But that’s just me.

To be continued?
Our work and existence, as media and people, is funded solely by our most generous supporters. But we’re not really covering our costs so far, and we’re in dire needs to upgrade our equipment, especially for video production.
Help SILVIEW.media survive and grow, please donate here, anything helps. Thank you!

! Articles can always be subject of later editing as a way of perfecting them

CLICK